Project Grant R01AI192629

The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $747,953 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for investigator-initiated research on lung-resident memory TH2 cells in asthma.

The project, R01AI192629, identifies pathways that mediate survival and maintenance of allergen-specific tissue-resident memory TH2 cells in specialized niches within the asthmatic lung. The research focuses on the CXCR6 chemokine system as a mechanism positioning TH2 cells in proximity to cells supplying survival signals for resident memory TH2 cell maintenance in allergic lungs. This work addresses allergic asthma—the most common asthma endotype—by targeting a cellular subset that drives recurrent asthma exacerbations despite current therapies targeting their mediators. The long-term objective is developing therapeutic approaches offering potential for lasting cure rather than chronic inflammation suppression.

The recipient is The General Hospital Corporation, doing business as Massachusetts General Hospital's Research Management Division, a Harvard Medical School teaching hospital and nonprofit academic medical center. Work is performed in Boston, Massachusetts.

The award runs from August 18, 2026, through July 31, 2031. The assistance type is a Project Grant, a competitive research grant supporting investigator-initiated biomedical research in infectious diseases and allergic conditions.